

GLAXOSMITHKLINE PLC
Form 6-K
April 18, 2017

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 18 April 2017

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

GlaxoSmithKline plc (the 'Company')

Transaction notification

Yes No x

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms E Walmsley
 b) Position/status Chief Executive Officer

c) Initial notification/
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.

c) Price(s) and volume(s)
 Price(s) Volume(s)
 £16.3903 14
 n/a (single transaction)

d) Aggregated information
 Aggregated volume Price

e) Date of the transaction 2017-04-13

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction London Stock Exchange
(XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr R G Connor
b) Position/status President, Global
Manufacturing & Supply
c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')
- b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 13
April 2017, on shares held
through the Company's Share
Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£16.3903 62
n/a (single transaction)
- d) Aggregated information
Aggregated volume Price
- e) Date of the transaction 2017-04-13
- f) Place of the transaction London Stock Exchange
(XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mr S Dingemans
b) Position/status Chief Financial Officer
c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.3903 20
d) Aggregated information	n/a (single transaction)
e) Date of the transaction	2017-04-13
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name	Mr N Hirons
b) Position/status	SVP, Global Ethics & Compliance
c) Initial notification/ amendment	Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.3903 7
d) Aggregated information	n/a (single transaction)

Aggregated volume Price

- e) Date of the transaction 2017-04-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr S A Hussain
- b) Position/status President, Global Pharmaceuticals

- c) Initial notification/ amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)
Price(s) Volume(s)
£16.3903 13
n/a (single transaction)

Aggregated information

- d) Aggregated volume Price

- e) Date of the transaction 2017-04-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D S Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ Initial notification

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£16.3903	70
n/a (single transaction)	
 - d) Aggregated information
Aggregated volume Price
 - e) Date of the transaction 2017-04-13
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms C Thomas
 - b) Position/status SVP, Human Resources
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares following the

re-investment of dividends
paid to shareholders on 13
April 2017, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.3903 70
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-13
f) Place of the transaction London Stock Exchange
(XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr P C Thomson
b) Position/status President, Global Affairs

c) Initial notification/
amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc
b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transaction(s) has been conducted

a) Description of the financial instrument Ordinary shares of 25 pence
each ('Ordinary Shares')

b) Nature of the transaction ISIN: GB0009252882
Acquisition of Ordinary
Shares following the
re-investment of dividends
paid to shareholders on 13
April 2017, on shares held
through the Company's Share
Reward Plan.

c) Price(s) and volume(s)
Price(s) Volume(s)
£16.3903 37
n/a (single transaction)

Aggregated information

d) Aggregated volume Price

e) Date of the transaction 2017-04-13

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Dr P J T Vallance
- b) Position/status President, R&D
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
- ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|--------------------------|-----------|
| £16.3903 | 42 |
| n/a (single transaction) | |
- d) Aggregated information
- Aggregated volume Price
- e) Date of the transaction 2017-04-13
- f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Mrs V A Whyte
- b) Position/status Company Secretary
- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

a) Description of the financial instrument	Ordinary shares of 25 pence each ('Ordinary Shares')
b) Nature of the transaction	ISIN: GB0009252882 Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 13 April 2017, on shares held through the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £16.3903 50 n/a (single transaction)
d) Aggregated information	
Aggregated volume	Price
e) Date of the transaction	2017-04-13
f) Place of the transaction	London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: April 18, 2017

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc